ATE340260T1 - Verfahren zur behandlung von tumoren mittels antiangiogener substanzen - Google Patents

Verfahren zur behandlung von tumoren mittels antiangiogener substanzen

Info

Publication number
ATE340260T1
ATE340260T1 AT00930428T AT00930428T ATE340260T1 AT E340260 T1 ATE340260 T1 AT E340260T1 AT 00930428 T AT00930428 T AT 00930428T AT 00930428 T AT00930428 T AT 00930428T AT E340260 T1 ATE340260 T1 AT E340260T1
Authority
AT
Austria
Prior art keywords
nucleic acid
antiangiogenic protein
recombinant nucleic
antiangiogenic
acid encoding
Prior art date
Application number
AT00930428T
Other languages
English (en)
Inventor
Steven K Libutti
Andrew Feldman
Original Assignee
Us Gov Health & Human Serv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Us Gov Health & Human Serv filed Critical Us Gov Health & Human Serv
Application granted granted Critical
Publication of ATE340260T1 publication Critical patent/ATE340260T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/027—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a retrovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
AT00930428T 1999-05-07 2000-05-05 Verfahren zur behandlung von tumoren mittels antiangiogener substanzen ATE340260T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US13324399P 1999-05-07 1999-05-07

Publications (1)

Publication Number Publication Date
ATE340260T1 true ATE340260T1 (de) 2006-10-15

Family

ID=22457666

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00930428T ATE340260T1 (de) 1999-05-07 2000-05-05 Verfahren zur behandlung von tumoren mittels antiangiogener substanzen

Country Status (7)

Country Link
EP (1) EP1179061B1 (de)
JP (1) JP2003510015A (de)
AT (1) ATE340260T1 (de)
AU (1) AU781134B2 (de)
CA (1) CA2372699A1 (de)
DE (1) DE60030850T2 (de)
WO (1) WO2000068379A1 (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020115202A1 (en) * 1999-08-13 2002-08-22 Paul Hallenbeck Adenoviral vectors including dna sequences encoding angiogenic inhibitors
AU2004308484A1 (en) * 2003-12-23 2005-07-14 The Trustees Of The University Of Pennsylvania Compositions and methods for combined therapy of disease
CN110664996B (zh) * 2019-11-04 2023-08-25 董红燕 Pedf来源的多肽复合物在制备治疗肺癌药物中的应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU692152B2 (en) * 1993-03-17 1998-06-04 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Immunogenic chimeras comprising nucleic acid sequences encoding endoplasmic reticulum signal sequence peptides and at least one other peptide, and their uses in vaccines and disease treatments
WO1997016169A1 (en) * 1995-11-01 1997-05-09 Chiron Corporation Treatment of a cardiovascular indication by delivery of therapeutics to the pericardial space
US5904144A (en) * 1996-03-22 1999-05-18 Cytotherapeutics, Inc. Method for treating ophthalmic diseases
WO1998049321A2 (en) * 1997-04-28 1998-11-05 Rhone-Poulenc Rorer S.A. Adenovirus-mediated intratumoral delivery of an angiogenesis antagonist for the treatment of tumors
AU7471098A (en) * 1997-04-30 1998-11-24 Mount Sinai School Of Medicine Of The City University Of New York, The Recombinant influenza viruses expressing tumor-associated antigens as antitum or agents

Also Published As

Publication number Publication date
DE60030850T2 (de) 2007-09-20
EP1179061A1 (de) 2002-02-13
DE60030850D1 (de) 2006-11-02
AU4824900A (en) 2000-11-21
JP2003510015A (ja) 2003-03-18
EP1179061B1 (de) 2006-09-20
AU781134B2 (en) 2005-05-05
WO2000068379A1 (en) 2000-11-16
CA2372699A1 (en) 2000-11-16

Similar Documents

Publication Publication Date Title
NO20013701D0 (no) HER-2/neu-fusjonsproteiner
HUP0002095A2 (hu) Vegyületek prosztatarák immunterápiás kezelésére és alkalmazásuk
DE69736981D1 (de) In vitro verfahren zum einbringen von nukleinsäuren in eine zelle
ATE355381T1 (de) Verfahren zur induzierung von genexpression mittels ionisierender strahlung
DE69934967D1 (de) Verfahren zur verminderung der immunogenität von proteinen
DE60229059D1 (de) Proteomimetische verbindungen und verfahren
TW200728465A (en) Compositions and methods for the therapy and diagnosis of prostate cancer
EA200901129A1 (ru) Нуклеиновые кислоты и полипептиды нового рецептора
ATE451835T1 (de) Therapeutische verfahren und zusammensetzungen unter verwendung von viren der rekombinanten familie der paramyxoviridae
ATE91630T1 (de) Pharmazeutische zusammensetzung zur verhuetung oder heilung von durch den papillomavirus induzierten tumoren.
DE60132190D1 (de) Mutierte version der arginin deiminase
BR0209990A (pt) Peptìdeos efetivos no tratamento de tumores e outras condições que requerem a remoção ou destruição de células
ATE546155T1 (de) Verfahren zur stabilisierung eines kryopräzipitats von plasmatischen proteinen für eine wärmebehandlung zur viralen inaktivierung
ATE368110T1 (de) Zusammensetzung und verfahren zur behandlung von immunverwandten krankheiten
EP1499190A4 (de) Verfahren zur behandlung von lebererkrankungen und leberschäden mit wachstumshormon und foxm1b
DE602004015142D1 (de) Antiangiogene peptide zur behandlung oder vorbeugung von endometriose
ATE340260T1 (de) Verfahren zur behandlung von tumoren mittels antiangiogener substanzen
ATE356145T1 (de) Polypeptide zur regenerierung des nervensystems
AU2003234342A8 (en) Ablated slam-dependent entry
ATE419389T1 (de) Sak: modulation der zellproliferation zur krebsbehandlung
ATE241387T1 (de) Verfahren zur in vivo dns-verabreichung durch verwendung eines nadelfreien geräts
DE602005006809D1 (de) Behandlung von nicht-alkoholischer steatotischer hepatitis (nash)
ATE329600T1 (de) Verwendung von tagatose zur verbesserung wichtiger blutfaktoren
ATE391777T1 (de) Verwendung von prohibitin-rns in krebsbehandlung
DE69942837D1 (de) Systemisches virus/ligand genabgabemittel und gentherapie

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties